Related Experiment Video
Updated: Jul 23, 2025
Bio-layer Interferometry for Measuring Kinetics of Protein-protein Interactions and Allosteric Ligand Effects
Published on: February 18, 2014
Molecular Dynamics Simulations Combined with Markov Model to Explore the Effect of Allosteric Inhibitor Binding on
Xiaotang Yang1, Yilin Gao1, Fuyan Cao1
1Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, 2699 Qianjin Street, Changchun 130012, China.
Abstract:
Bromodomain-Containing Protein 4 (BRD4) can play an important role in gene transcriptional regulation of tumor development and survival by participating in histone modification epigenetic mechanism. Although it has been reported that novel allosteric inhibitors such as ZL0590 have a high affinity with target protein BRD4 and good efficacy, their inhibitory mechanism has not been studied further. The aim of this study was to reveal the inhibition mechanism of allosteric inhibitor ZL0590 on Free-BRD4 and BRD4 binding MS436 (orthosteric inhibitor) by molecular dynamics simulation combined with a Markov model. Our results showed that BRD4-ZL0590 led to α-helices formation of 100-105 compared with Free-BRD4; the combination of MS436 caused residues 30-40 and 95-105 to form α-helices, while the combination of allosteric inhibitors untangled the α-helices formed by the MS436. The results of Markov flux analysis showed that the binding process of inhibitors mainly involved changes in the degree of α-helices at ZA loop. The binding of ZL0590 reduced the distance between ZA loop and BC loop, blocked the conformation at the active site, and inhibited the binding of MS436. After the allosteric inhibitor binding, the MS436 that could normally penetrate into the interior of the pocket was floating on the edge of the active pocket and did not continue to penetrate into the active pocket as expected. In summary, we provide a theoretical basis for the inhibition mechanism of ZL0590 against BRD4, which can be used as a reference for improving the development of drug targets for cancer therapy.
Insights
This study reveals how the allosteric inhibitor ZL0590 works against Bromodomain-Containing Protein 4 (BRD4). ZL0590 alters BRD4
Area of Science:
- Molecular biology
- Epigenetics
- Drug discovery
Background:
- Bromodomain-Containing Protein 4 (BRD4) is a key epigenetic regulator in cancer development.
- Allosteric inhibitors like ZL0590 show promise against BRD4, but their precise inhibitory mechanisms require further elucidation.
- Understanding BRD4 inhibition is crucial for developing novel cancer therapies.
Purpose of the Study:
- To elucidate the inhibition mechanism of the allosteric inhibitor ZL0590 on Bromodomain-Containing Protein 4 (BRD4).
- To investigate the interplay between ZL0590 and the orthosteric inhibitor MS436 using computational methods.
- To provide a theoretical foundation for the rational design of BRD4-targeted cancer therapeutics.
Main Methods:
- Molecular dynamics (MD) simulations were employed to model the interactions of ZL0590 and MS436 with BRD4.
- Markov state modeling was utilized to analyze the dynamic pathways and conformational changes upon inhibitor binding.
- Analysis focused on secondary structure alterations, loop dynamics (ZA and BC loops), and active site accessibility.
Main Results:
- ZL0590 binding induced alpha-helix formation in specific BRD4 regions (residues 100-105), distinct from MS436 effects.
- Allosteric inhibition by ZL0590 disrupted MS436-induced alpha-helix formation, suggesting allosteric interference.
- Markov flux analysis indicated that inhibitor binding primarily affects alpha-helix dynamics at the ZA loop, altering active site conformation and blocking MS436 entry.
Conclusions:
- ZL0590 functions as an allosteric inhibitor by reducing the distance between ZA and BC loops, thereby blocking the BRD4 active site.
- The binding of ZL0590 prevents the orthosteric inhibitor MS436 from fully accessing the active pocket.
- This study provides critical insights into the allosteric inhibition mechanism of ZL0590 against BRD4, offering a valuable reference for future cancer drug development.
More Related Videos
Related Concept Videos
01:58Cooperative Allosteric Transitions
00:49Ligand Binding and Linkage
01:19Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
01:16Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
02:18The Equilibrium Binding Constant and Binding Strength
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...